Bull case
Cardiol Therapeutics is supported by a credible clinical thesis in recurrent pericarditis, where the peer-reviewed MAvERIC-Pilot showed rapid, durable symptom relief, a 3.7-point pain reduction at Week 8, and an annualized event rate falling from 5.8 to 0.9 during study participation. The ongoing Phase III MAVERIC trial reached its original 110-patient target and will expand to up to 150 patients after a lower-than-expected blinded event rate, with topline results pushed to mid-2027, but published rilonacept-withdrawal data showing ~75–82% recurrence suggests the low event rate may reflect CardiolRx efficacy rather than weak trial activity. Its oral, steroid-sparing profile could position it ahead of injectable IL-1 blockers or as a step-down therapy after biologics, while CRD-38 adds another optionality layer in inflammatory heart disease and heart failure.